"Radiopharmaceuticals" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161)
| Descriptor ID |
D019275
|
| MeSH Number(s) |
D27.505.259.843 D27.505.519.871 D27.720.470.410.650
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Radiopharmaceuticals".
Below are MeSH descriptors whose meaning is more specific than "Radiopharmaceuticals".
This graph shows the total number of publications written about "Radiopharmaceuticals" by people in this website by year, and whether "Radiopharmaceuticals" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 5 | 6 |
| 1999 | 1 | 2 | 3 |
| 2000 | 4 | 2 | 6 |
| 2001 | 2 | 1 | 3 |
| 2002 | 2 | 1 | 3 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 4 | 5 |
| 2006 | 2 | 1 | 3 |
| 2007 | 7 | 2 | 9 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 2 | 3 |
| 2010 | 2 | 2 | 4 |
| 2011 | 4 | 5 | 9 |
| 2012 | 2 | 6 | 8 |
| 2013 | 1 | 3 | 4 |
| 2014 | 4 | 2 | 6 |
| 2015 | 3 | 1 | 4 |
| 2016 | 2 | 9 | 11 |
| 2017 | 2 | 5 | 7 |
| 2018 | 2 | 5 | 7 |
| 2019 | 1 | 3 | 4 |
| 2020 | 6 | 6 | 12 |
| 2021 | 1 | 3 | 4 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 3 | 3 |
| 2024 | 3 | 3 | 6 |
| 2025 | 2 | 3 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Radiopharmaceuticals" by people in Profiles.
-
A concise review on MDM2 inhibitors and recent progress in radiopharmaceutical development for imaging MDM2 expression in tumors with PET or SPECT. Bioorg Med Chem Lett. 2025 Dec 15; 129:130394.
-
Molecular PET imaging: Unlocking the secrets of cancer metabolism. Biochem Pharmacol. 2025 Dec; 242(Pt 3):117202.
-
Association of integrated biomarkers and progression-free survival prediction in patients with gastroenteropancreatic neuroendocrine tumors undergoing [177Lu]Lu-DOTA-TATE therapy. Theranostics. 2025; 15(13):6444-6453.
-
Accuracy of 18F-Fluorodeoxyglucose Positron Emission Tomography in Early Metastatic Testicular Seminoma: Analysis From the SEMS Trial. J Urol. 2025 Sep; 214(3):272-279.
-
PET/CT: Interpretative Pitfalls in the Thorax. Radiol Clin North Am. 2025 Jul; 63(4):553-563.
-
A Pharmacokinetic Model Determination of Time Activity Curves in Radiopharmaceutical Therapy. Mol Imaging. 2024 Jan-Dec; 23:15353508241280015.
-
Surgery enhances the effectiveness of peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumors. Surgery. 2025 01; 177:108834.
-
Quantitative SSTR-PET/CT: a potential tool for predicting everolimus response in neuroendoctine tumour patients. Radiol Oncol. 2024 09 01; 58(3):348-356.
-
In Vivo Mapping of Myocardial Injury Outside the Infarct Zone: Tissue at an Intermediate Pathological State. J Am Heart Assoc. 2024 May 07; 13(9):e032577.
-
Modified Radiation Lobectomy Strategy of Radioembolization for Right-Sided Unresectable Primary Liver Tumors. J Vasc Interv Radiol. 2024 07; 35(7):989-997.e2.